Divi’s Laboratories Limited (NSE: DIVISLAB), a leading Indian API manufacturer, posted consolidated total income of INR 2,692 crores for Q3 FY26 ended December 31, 2025, reflecting a 12% year-over-year increase from INR 2,401 crores.
Q3 FY26 Consolidated Performance
Profit before tax (PBT) reached INR 780 crores, up from INR 726 crores in the prior year’s quarter, though adjusted for a one-time INR 74 crore labour codes impact. Profit after tax (PAT) stood at INR 583 crores, slightly below the INR 589 crores recorded in Q3 FY25. Forex gains contributed positively, amounting to INR 19 crores versus INR 10 crores last year. These figures highlight resilient operations despite regulatory costs.
Nine-Month FY26 Results
For the nine months ended December 31, 2025, consolidated total income grew to INR 8,081 crores from INR 7,041 crores, a robust 15% YoY rise. PBT advanced to INR 2,425 crores, incorporating the same INR 74 crore labour codes charge, compared to INR 2,052 crores previously. PAT climbed 19% to INR 1,817 crores from INR 1,529 crores. Forex gains bolstered performance at INR 121 crores, more than tripling the prior period’s INR 38 crores.
Operational Context
Divi’s Laboratories continues to benefit from strong demand in active pharmaceutical ingredients (APIs) and custom synthesis, driving top-line growth across both quarterly and nine-month periods. The slight Q3 PAT dip reflects the labour codes provision, which did not recur in the base period, while nine-month gains demonstrate underlying profitability momentum. Enhanced forex gains signal effective currency management amid global volatility.
Overall, these results position Divi’s Laboratories for sustained performance in FY26, supported by capacity expansions and a favourable product pipeline.